Form 3 Filing for David Allen Stamler - Alterity Therapeutics Ltd

This filing reports on Form 3, Initial Statement of Beneficial Ownership, for David Allen Stamler, Chief Executive Officer and Director of Alterity Therapeutics Ltd. The report details direct ownership of 11,688,312 ordinary shares. Additionally, it lists holdings of various options, including: a listed option expiring February 26, 2027, for 1,515,152 ordinary shares at an exercise price of $0.028; a listed option expiring August 31, 2026, for 2,380,952 ordinary shares at an exercise price of $0.01; an unlisted option expiring March 21, 2029, for 40,000,200 ordinary shares at an exercise price of $0.003; and an unlisted option expiring August 8, 2030, for 290,400,000 ordinary shares at an exercise price of $0.0086. Indirect ownership includes 139,258 American Depositary Shares, representing 600 ordinary shares each, held through HSBC Custody Nominees (Australia) Limited.